Comments
Suven Life Sciences has received four product patents for its new chemical entities (NCEs), which could be used in the treatment of various central nervous system disorders.
The four product patents, one from Europe, two from Sri Lanka and one from Korea, are valid through 2027, 2025 and 2024, respectively, the company said in a statement today.
“We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders, which has an estimated $30-billion market potential globally,” Suven Life Sciences CEO, Mr Venkat Jasti, said.
The company has received the approval for molecules that could be used in the treatment of CNS disorders like Parkinson’s, Alzheimer’s and Schizophrenia.
Products out of these inventions may be out-licensed at various phases of clinical development like Phase-I or Phase-II, the statement said.
With these new patents, the company has a total of 11 from Europe, eight patents from Sri Lanka and five patents from Korea.
Meanwhile, the shares of Suven Life Sciences were being quoted at Rs 17.50 in the afternoon trade on the Bombay Stock Exchange (BSE) today, up 1.45 per cent from the previous close.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.